mHSPC
Metastatic hormone-sensitive prostate cancer
Advertisement
Is it possible to avoid or delay systemic therapy for patients with oligometastatic prostate cancer? A new study suggests so.
An analysis highlighted real-world treatment of patients with mHSPC in the community who received at least 1 line of therapy.
Tanya Dorff, MD, shares the barriers to utilizing PARP inhibitors plus AR-targeted agents in early prostate cancer settings.
Dr. Deek shares what research should be done to better personalize care for patients with oligometastatic prostate cancer.
Dr. Deek shares what “high-risk mutation” signified in his study and how patients with “high-risk mutation” should be ...
Dr. Deek shares how PSMA imaging used in both the STOMP and ORIOLE trials.
Dr. Deek shares how he evaluated long-term outcomes of MDT in om CSPC in both the ORIOLE and STOMP trials.
While PSMA-RLT is typically used during later disease stages, patients in earlier disease stages may benefit as well.
Liquid biopsy of CTCs may serve as an effective prediction biomarker for docetaxel response in patients with CRPC and mHSPC.
High testosterone levels measured by a liquid chromatography-tandem mass spectrometry assay may predict castration response.
Daniel George, MD, Duke University School of Medicine, gives us insight on what to expect from the future of mHSPC treatment.
Neeraj Agarwal, MD, Professor of Medicine, gives his outlook on the future of cancer care and treatment for mHSPC in 2027.
Michael Morris, MD, of Memorial Sloan Kettering Cancer Center gives his predictions for the future of mHSPC treatment.
Abiraterone acetate + prednisolone is compared to enzalutamide + AAP for mHSPC cancer starting androgen-deprivation therapy.
Zoledronic acid did not improve survival outcomes in patients outside of metastatic castration-resistant disease.
Late-breaking data from 2 randomized phase 3 trials that followed STAMPEDE protocol were presented at the ESMO Congress 2022.
The FDA has approved the use of darolutamide in combination with docetaxel for metastatic hormone-sensitive prostate cancer.
Researchers evaluate the frequency of germline DDRg mutations in metastatic prostate cancer patients of different ancestries.
Advertisement
670 Madison Ave.
Manalapan, NJ 07726